About PolyTherics

PolyTherics is a biotechnology company that applies precision chemistry to develop protein and peptide-based drugs. These two classes of drugs are administrated to patients by injection and are generally cleared from the body very quickly. This rapid clearance can reduce the efficacy of the drug and increase the frequency that injections have to be administrated to patient. Our precision chemistry technologies can extend the duration of action of these classes of drugs so patients require fewer injections, and can create more efficacious products. This reduces the cost of treatment and improves patient compliance. 

PolyTherics has three proprietary precision chemistry technologies for attaching one or more molecules of the polymer poly (ethylene glycol) (PEG) to any therapeutic peptide or protein to slow its elimination from the body.

PolyTherics acquired Warwick Effect Polymers in January 2012 and now offers two additional polymers, PolyPEG and GlycoPol, to enable the development of better biopharmaceuticals. For further information please go to http://www.warwickeffectpolymers.co.uk

PolyTherics’ CEO discusses the company’s strategy, licensed deals and plans for growth

PEGylation is an established method for improving medicines and nine PEGylated products are already approved for use in either the US and/or EU. PolyTherics’ methods of PEGylation add PEG to a specific site on proteins and peptides producing a more homogeneous product than traditional PEGylation technologies.

The market for therapeutic proteins is expected to grow to $160.1 Bn by 2013. PolyTherics has positioned its business to work in partnership with biopharmaceutical companies to produce better products to capitalize on this enormous market opportunity. The Company believes in collaboration to access therapeutic proteins and peptides, and complementary expertise, and pursues opportunities to expand its exploratory research under grant-funded initiatives.

For information on the Company’s history
click here.